The registration of novel excipients
Here, Dave Elder discusses some encouraging progress in the development of novel excipients, highlighting what this means for the industry.
List view / Grid view
Articles
Many hands make light work: why the new Bespoke Gene Therapy Consortium is a godsend for ambitious biopharma teams
In late October, we learned that an exciting and ambitious new entity – the Bespoke Gene Therapy Consortium (BGTC) – had come into being in the US, designed to encourage the delivery of more gene therapies for rare diseases. The consortium is an interesting construct, headed and funded by the…
QA/QC Raman & RMM In-Depth Focus 2021
In this in-depth focus, discover how Raman spectroscopy is used by Bristol-Myers Squibb to identify counterfeit pharmaceuticals and the role of artificial intelligence in rapid microbiological method development.
Challenges and innovations shaping the bioprocessing industry
In this article, Robert Newman and Tom Fletcher explore how the bioprocessing industry has changed in the last 50 years and where the future may lead…
Future proofing risk assessment: preventing the next nitrosamine incident
The valsartan nitrosamine contamination issue was probably the most significant quality issue to hit the pharmaceutical industry in a decade. Here, Dave Elder outlines how agencies and manufacturers are dealing with the problem and indicates the knowledge gaps that might be concealing future complications.
European Pharmaceutical Review Issue 6 2021
This journal features articles discussing what knowledge could help the industry to prevent the next nitrosamine-like contamination event, the key steps when validating analytical techniques for cell and gene therapies and how artificial intelligence is shaping microbiology. Also in this issue, using Raman spectroscopy and hyperspectral imaging to detect counterfeit…
Generic drug market growth: insights to 2030
The global generics drug market is anticipated to grow to $574.63 billion by 2030, owing to the increasing application of robotic process automation, branded medicine patent expiries and the rising prevalence of chronic diseases.
Seeing more from every sample: using AI image analysis to transform clinical decision-making
Artificial intelligence (AI)-based image analysis tools have the potential to completely revolutionise cancer diagnostics, saving time and money by reducing the need for lab testing and expanding global access to cancer diagnostic services. Here, Pahini Pandya, CEO Panakeia Technologies, discusses such technologies and their potential benefits.
Five marketing strategies for novel therapeutics
Long before the advent of Coronavirus, next-generation therapies were making headlines, but the successful development of COVID-19 vaccines, including mRNA vaccines, has now shone a spotlight on next-generation therapies. This offers a boost to the long-term growth projections for the advanced therapy medicinal products (ATMPs) sector. But although ATMPs hold…
Technologies and tactics for accelerating end-to-end biologic drug development
Creating new biologic drugs from early research is a complex process, but certain development methodologies and practices are proving to reach clinical and commercial goals faster. In this article, Seahee Kim from Samsung Biologics provides insight into how contract development and manufacturing organisations (CDMOs) are applying new and effective methodologies…
What to consider when formulating bacteriophages
In this article, Dr Michael Koeris, Associate Professor, Bioprocessing at Keck Graduate Institute, and Carolina Moraes de Souza, Keck MEng graduate, now Process Development Senior Associate at Amgen, discuss the key formulation considerations for bacteriophages, a potential solution to antimicrobial resistance, and why process development should be an early consideration.
Social media is transforming our understanding of drug safety
Here, Daniel Ghinn of CREATION.co discusses the growing role social media analysis is playing in helping to provide pharmaceutical companies and health regulators with real-world evidence on drug safety.
Developing drug pipelines
Kris Sterkens, Company Group Chairman of Janssen EMEA and Managing Director of Janssen Pharmaceutica considers how alterations made to COVID-19 vaccine development procedures could benefit future drug development pipelines.
Is PSS Insourcing Solutions right for you?
Patricia Grace, Senior Director, Eurofins Professional Scientific Services (PSS) Europe, shares reasons for the success of the model within the bio/pharma industry.
The complex relationship between biopharmaceuticals and sustainability
The biopharmaceutical industry performed significantly above average in EcoAct’s Climate Reporting Performance analysis – but what steps are big pharma companies taking to improve sustainability and how much further do they need to go?
